Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. (linkinghub.elsevier.com)

Authors: Horn DB … Jouravskaya I Journal: The Lancet Published: 2025-11-20 DOI: https://doi.org/10.1016/S0140-6736(25)02165-8